A new study has uncovered how the immune system locks developing cells into the type 1 classical dendritic cell, or cDC1, lineage—an immune cell population that plays a central role in detecting viral threats and activating killer T cells. Published in Nature Immunology, the research identifies a previously unrecognized molecular partnership between the transcriptional regulator ID2 and a regulatory region controlling the gene Zeb2. The findings explain how developing blood cells are directed toward cDC1 identity and reveal why disrupting a handful of DNA-binding sites can dramatically reshape immune-cell production.
Dendritic cells act as an information bridge between innate and adaptive immunity. They sense signs of infection, process foreign proteins and present fragments of those proteins to T cells. Among them, cDC1s are especially efficient at cross-presentation, a process in which material captured from infected or abnormal cells is displayed to CD8-positive cytotoxic T cells. This function is crucial for antiviral defense because many viruses infect tissues or cell types that conventional antigen-presenting pathways do not efficiently expose to killer T cells. Yet cDC1s are produced in relatively small numbers, and the molecular events that specify them from common myeloid progenitors have remained incompletely understood.
The study focuses on ID2, a transcriptional regulator already known to be essential for cDC1 development. Transcriptional regulators control gene activity by binding DNA directly or by influencing other proteins that occupy regulatory regions. ID2 belongs to a family of proteins that can inhibit E proteins, a group of DNA-binding factors that recognize short sequences known as E-boxes. E proteins are involved in the development of several blood and immune lineages, particularly B cells, but their broader role during myelopoiesis—the production of myeloid cells—has been less clear. The new work shows that their activity is not simply supportive or disruptive across the entire immune system. Instead, it can have sharply different effects depending on the precise DNA site involved.
The researchers centered their investigation on a powerful enhancer located approximately 165 kilobases from the Zeb2 gene. Enhancers are stretches of regulatory DNA that can increase transcription when occupied by the appropriate combination of transcription factors. Although they may be physically distant from the genes they control, enhancers communicate with gene promoters through three-dimensional folding of the genome. The −165-kilobase Zeb2 enhancer had previously been linked to normal blood formation and was known to receive competing inputs from CEBP proteins and NFIL3 during the divergence of myeloid and dendritic-cell lineages. The new findings add E proteins and ID2 to this regulatory circuit, transforming the enhancer into a molecular decision-making center.
According to the study, E proteins bind E-box motifs within the Zeb2 enhancer and influence whether the enhancer remains active during immune-cell development. ID2 does not appear to function by simply turning on a cDC1-specific gene program on its own. Instead, it promotes cDC1 specification by antagonizing E protein activity at these particular E-boxes. This distinction is important. ID2 acts as a molecular brake on E proteins, preventing them from exerting their normal regulatory effects at a defined location in the genome. The result is not a universal suppression of E protein function, but a site-specific alteration in the regulatory logic controlling Zeb2.
To test the importance of these motifs, the researchers deleted the E-box sequences from the enhancer. The consequences were striking. Removing the sites eliminated the development of B cells and plasmacytoid dendritic cells, two immune populations that depend strongly on E protein-driven regulatory programs. At the same time, myelopoiesis was redirected toward the cDC1 lineage. This result demonstrates that the E-boxes are not passive DNA elements. They actively distribute developmental potential among competing immune-cell fates, allowing the same enhancer to support different outcomes depending on which motifs are occupied and which transcriptional regulators are present.
The genetic experiments also produced a particularly important result for understanding ID2. In mice lacking Id2, cDC1 development is normally severely impaired. However, deleting the E-boxes within the Zeb2 enhancer rescued cDC1 production even in the absence of ID2. This finding places the E-boxes directly downstream of, or functionally within, the pathway controlled by ID2. If removing the DNA sites can compensate for loss of the inhibitor, then ID2’s essential role in cDC1 specification is at least partly to restrain E protein activity at those positions. The experiment provides unusually direct evidence that a transcription factor can establish cell fate by blocking the action of another factor at selected genomic sites.
The researchers propose a two-step model for how the cDC1 program becomes stabilized. Early in the developmental process, NFIL3 transiently represses Zeb2, helping establish a temporary state during myeloid and dendritic-cell divergence. Later, ID2 antagonizes E proteins at the E-boxes in the −165-kilobase enhancer. This second intervention prevents the regulatory program from reverting toward alternative lineages and secures the cDC1 identity. In this model, cDC1 specification is not triggered by a single decisive switch. It is built progressively, first through transient repression and then through selective inhibition that stabilizes the chosen fate.
The study describes this arrangement as “site-specific pleiotropy.” In biology, pleiotropy refers to one element influencing multiple traits or outcomes. Here, a single enhancer controls different developmental routes through distinct transcription-factor motifs. E-boxes help regulate B-cell and plasmacytoid dendritic-cell production, while CEBP-binding sites contribute to other myeloid decisions, and the combined activity of NFIL3, ID2 and E proteins changes the enhancer’s effect over time. This means that regulatory DNA cannot always be understood as having one fixed function. Its output depends on the exact sequence of motifs, the proteins available in a developing cell and the stage at which those proteins act.
The findings may have broad implications for antiviral immunology and immune-cell engineering. Because cDC1s are highly effective at presenting viral and tumor antigens to CD8-positive T cells, understanding the enhancer logic that produces them could eventually help researchers improve dendritic-cell generation in the laboratory or design therapies that strengthen antigen presentation. The work also cautions against treating transcription factors as uniformly activating or repressing agents. ID2, E proteins, NFIL3 and CEBP proteins can produce very different biological outcomes according to where they bind and which regulatory elements they share. By revealing how a small set of DNA motifs can redirect the balance between multiple immune lineages, the study offers a more precise view of blood-cell development—and a potential molecular framework for manipulating immune responses against infection.
Subject of Research: The molecular regulation of cDC1 specification during hematopoiesis, focusing on ID2, E proteins and the −165-kilobase Zeb2 enhancer.
Article Title: ID2 secures cDC1 specification by antagonizing E proteins at a pleiotropic Zeb2 enhancer
Article References: Ou, F., Liu, TT., Du, S. et al. ID2 secures cDC1 specification by antagonizing E proteins at a pleiotropic Zeb2 enhancer. Nat Immunol (2026). https://doi.org/10.1038/s41590-026-02632-1
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41590-026-02632-1
Keywords: ID2, E proteins, cDC1, Zeb2 enhancer, NFIL3, CEBP, myelopoiesis, dendritic cells, hematopoiesis, antiviral immunity
Tags: cDC1 lineage specificationdendritic cell developmentdisruption of dendritic cell gene regulationDNA-binding sites in immune cell fate decisionsID2 transcriptional regulatorimmune cell lineage commitmentimmune system regulation by transcription factorsmolecular mechanisms of dendritic cell differentiationregulation of cross-presentation in dendritic cellsrole of E proteins in immune cell developmenttranscriptional control of antiviral immune responsesZeb2 gene regulation
